Definitive Contract HHSN261201400022C

<p>This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), a civilian federal agency, to Transgenex Nanobiotech Inc., a minority-owned small business, for the development of a &quot;fibrous scaffold-induced spheroids mimicking TME&quot; solution. The contract, valued at $299,992.00, is a definitive, firm fixed-price contract with a completion date of July 21, 2014. The contract was set aside for the participation of small businesses.</p>

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

This is a $225,000.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a Minority Owned, For Profit, Subcontinent Asian (Asian-Indian) American Owned business. The contract is for &quot;SBIR PHASE I - FISS-CSC: A FIBER-INSPIRED SMART SCAFFOLD PLATFORM FOR EXPANDING CANCER STEM CELLS&quot; and was awarded on September 22, 2015 with a completion date of August 21, 2016. This appears to be a Small Business Innovation Research...

<p>The National Cancer Institute awarded a $224,999.00 Firm Fixed Price definitive contract to Transgenex Nanobiotech Inc., a minority-owned for-profit business, to develop anti-NPRA inhibitors targeting cancer stem cells in tumoroids. The contract has a completion date of September 11, 2015 and is not associated with any set-aside designation. Transgenex Nanobiotech Inc. has received previous federal contract and grant awards, with the most recent contract award on February 1, 2017.</p>

This is a federal contract awarded by the National Cancer Institute (NCI), a civilian agency, to Pointcare Genomics Corp, a small minority-owned business, for research and development in biomedical basic research. The contract is a definitive, firm-fixed price contract valued at $299,961.00 and is part of the SBIR (Small Business Innovation Research) Program Phase I. The contract has a total small business set-aside designation and was awarded on September 22, 2015, with a completion date of...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&amp;D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&amp;D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...

This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute (NCI) to Inlighta Biosciences L.L.C., a woman-owned small business. The $298,230.00 firm fixed-price contract is for a Phase I Small Business Innovation Research (SBIR) project titled &quot;Non-Invasive Subtyping of Aggressive Tumor and Its Environment&quot; as part of the NCI Cancer Moonshot initiative. The original solicitation was issued under the NIH/CDC...

This is a $289,828.00 SBIR Phase I contract awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Nicolalde R&amp;D LLC, a minority-owned, self-certified small disadvantaged business. The contract is a firm fixed-price definitive contract with a completion date of November 30, 2021. The SBIR (Small Business Innovation Research) Program Phase I award indicates this contract is for early-stage research and development activities. As a...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Targagenix, Inc. for R&amp;D on a nanoemulsion formulation and IND-enabling studies of a novel cancer stem cell cytotoxic agent. The definitive, firm-fixed-price contract has a ceiling value of $2,284,577.00 and a period of performance ending on October 15, 2018. As an SBIR Phase I award, this contract supports early-stage research and development...

This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...